To compare the effects of low-dose versus high-dose subcutaneous ( SC ) aldesleukin (
interleukin-2; IL-2 ) on immunologic and virologic markers in HIV-infected patients. To
compare the effects of monthly versus bimonthly administration of SC IL-2 on these markers.
Interleukin-2 is a protein that is naturally produced by lymphocytes. In an initial study,
patients in an earlier stage of HIV-1 infection tended to tolerate SC IL-2 better than those
with more advanced infections, and those with higher baseline CD4+ counts tended to derive
the greatest benefit.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)